News
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...
The drugmaker is still dealing with the fallout over its HPV vaccine Gardasil in China, where a drop in demand forced it to halt shipments and rescind its previous forecast of $11 billion in ...
Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between the US and China, where demand for its blockbuster Gardasil vaccine is ...
Bell noted that Gardasil labeling approved by the U.S. from 2006 to the present includes no warnings on POTS or POI, adding that HHS "has consistently opposed allegations of a causal connection in ...
Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...
In its rush to market its human papillomavirus vaccine, Merck forgot to make a strong and compelling case for compulsory immunization. Merck's human papillomavirus (HPV) vaccine Gardasil should ...
(Reuters) -Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil ...
Merck MRK-N said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year forecast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results